同步放化疗与单纯放疗治疗中晚期宫颈癌的临床疗效比较

摘要

Objective:To compare the clinical effect between concurrent chemoradiotherapy and only radiotherapy for advanced cervical carcinoma.Methods: 126 cases with advanced cervical carcinoma were randomly divided into only radiotherapy group and concurrent chemoradiotherapy group. 60 cases of only radiotherapy group were given routine radiotherapy and 66 patients of concurrent chemoradiotherapy group received cisplatin and paclitaxel chemoradiotherapy based on radiotherapy.Results:The effective rates were 86.4% and 56.7% in concurrent chemoradiotherapy group and only radiotherapy group respectively with significant difference (P<0.01);3 year survival rate of concurrent chemoradiotherapy group was much higher than that of only radiotherapy group (75.8%vs58.3%,P<0. 05);Recurrence rate and metastasis rate in concurrent chemoradiotherapy group were 9.1% and 7.6%,which were much lower than that in only radiotherapy group(16.7%vs l8.3%,P<0.05);Compared with only radiotherapy group,incidence of adverse reaction in concurrent chemoradiotherapy group was greatly increased (P<0.05).Conclusion:Compared with only radiotherapy,concurrent chemoradiotherapy for advanced cervical carcinoma can greatly improve the 3 year survival rate and prognosis of patients.%目的:比较同步放化疗与单纯放疗治疗中晚期宫颈癌的临床疗效.方法:将126例中晚期宫颈癌患者随机分入同步放化疗组与单纯放疗组,给予60例单纯放疗组患者常规放疗,66例同步放化疗组患者在常规放疗基础上,同时给予顺铂及紫杉醇同步化疗.结果:同步放化疗组与单纯放疗组治疗总有效率分别为86.4%和56.7%,差别具有统计学意义(P<0.01);同步放化疗组3年生存率显著高于单纯放疗组(75.8%vs58.3%,P<0.01);同步放化疗组复发率和远行转移率分别为9.1%和7.6%,显著低于单纯放疗组(16.7%vs18.3%,P<0.05);同步放疗组不良反应发生率显著高于单纯放疗组(P<0.05),消化道反应和骨髓抑制为最常见的不良反应,患者均能耐受.结论:与单纯放疗相比,同步放化疗治疗中晚期宫颈癌可显著提高患者3年生存率,改善预后.